Company intelligence / Profile preview

Bioharmony Therapeutics

New York, New York, United Statesbioharmonytherapeutics.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Bioharmony Therapeutics has developed a portfolio of lysin-based antimicrobials targeting multidrug-resistant Gram-negative bacterial infections. Its lead programs are in preclinical development and have shown promise as novel therapeutics with a new mechanism of action that may overcome traditional antibiotic resistance. The company has partnered with Boehringer Ingelheim to advance its systemic lysin candidates for hospital-acquired and life-threatening infections such as those caused by Acinetobacter species.[3][5] No clinical results have been published yet.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Enzymes (lysin-based biologics)Synthetic peptides[2][4]
Industry: Biotech

Drug pipeline

1 asset

BH-01

Preclinical

Partnerships

Boehringer Ingelheim (collaboration to develop lysins for MDR Acinetobacter)[3][5]

Beyond the preview

Go deeper on Bioharmony Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioharmony Therapeutics.